Medi First R&D combines genetics, formulation science, and drug-delivery approaches into an integrated development process - starting from Target Product Profiles (TPP) and clinical requirements.
In phytomedicine, a gap still exists between therapeutic potential and robust, comparable evidence. Divergent product profiles and inconsistent dosing logics make clinical decisions difficult. Our research addresses these bottlenecks through standardization, formulation development, and defined evidence pathways.
Scientific foundation
Cannabinoid-based therapies require a clear classification within pharmacology, the endocannabinoid system (ECS), and formulation science. Our focus is on profiles that can be standardized, dosed, and clinically evaluated. You are welcome to request details on methodology, criteria catalogues, and development logic.
Get in touch now
Genetics & Chemovar Design
The selection and characterization of defined profiles serve as the starting point for standardized active-ingredient and full-spectrum approaches.
Focus
- Profile characterization (cannabinoids, terpenes, additional metabolites)
- Selection along defined target parameters (TPP)
- Profile stability and reproducibility across batches
Pharmaceutical Formulation Science
Formulation science determines dosability, stability, and applicability. We develop formulations so that dosing and use are practical in everyday clinical settings and support therapy adherence.
Focus
- Formulation design for a defined dosing logic
- Stability and compatibility logic
- Practice-oriented dosage forms (considered from the development side)
Drug-Delivery Technology
Technology pathways to optimize bioavailability, including liposomal systems and nano-emulsions, along defined target parameters.
Focus
- Bioavailability as a design parameter (TPP-bound)
- Concepts for controlled uptake and reproducible use
- Delivery forms that support tolerability and everyday suitability (e.g., transdermal systems)
Cultivation Systems (TPP-guided)
Cultivation is part of the design: it affects profile complexity, standardization, and scalability.
Two setups - one benchmark: the target profile (TPP)
Focus
- Biophilic living-soil setups: for complex metabolite profiles when profile breadth is part of the objective
- Sterile aero-/hydroponic systems: for highly standardized isolates and defined purity
Target Product Profile (TPP)
Prototyping
Evidence Generation
Evidence generation (preclinical · observational · clinical) iteratively feeds back into TPP and prototyping.
Scientific leadership
PhD candidate Gabriel Hentschel leads the scientific strategy at the interface of research and clinical application, with a focus including neurology and clinical safety.
Scientific LeadGet in touch now
Platform inquiries
We provide technical details, criteria catalogues, and project frameworks selectively in the context of specific collaborations.
Send project inquiry
Provision after qualification, possibly NDA-based.
Information on this website is intended for professional and collaboration partners. No medical advice and no individual therapy recommendations.
